Contrast enhancement of vascular walls of intracranial high flow malformations in black blood MRI indicates high inflammatory activity

Athanasios K. Petridis 1*, Maxine Dibue-Adjei 2, Jan F. Cornelius 1, Marian Preetham Suresh 1, Lan Li 4, Marcel A. Kamp 1, Yousef Abusabha 1, Bernd Turowski 3, Hans Jakob Steiger 1 and Rebecca May 3

Abstract

Background: There are controversies concerning the natural history of arteriovenous malformations (AVMs) in literature and it is not clear which AVMs should be treated and which should be just observed. Objective criteria beyond growth in serial MRIs or angiographies are needed. The use of black blood MRI is currently under investigation for evaluating the rupture risk of cerebral aneurysms, however its use for assessment of AVMs has yet to be evaluated. We therefore conducted a feasibility study on the application of black blood MRI (bbMRI) in AVMs to assess rupture risk.

Methods: Retrospective study of 10 patients with intracranial AVMs and 4 patients with arteriovenous fistulas who received a black blood MRI before treatment.

Results: AVM niduses (9/10) show contrast enhancement irrespective of rupture or size. All arteriovenous fistulas (4 / 4) were contrast enhancing irrespective of rupture.

Conclusion: High flow malformations are in a permanent stage of inflammation which does not seem to allow conclusions on their rupture risk at the current stage. BbMRI is a feasible method of identifying inflammation in AVMs and arteriovenous fistulas. However, future prospective studies are needed to evaluate whether bbMRI contrast enhancement correlates with rupture risk.

Keywords: Arteriovenous malformation, Arteriovenous fistula, Black blood MRI, Inflammation

Background

The natural history of arteriovenous malformations (AVMs) represents a controversial topic. While the ARUBA study shows a low rupture risk, epidemiologic studies suggest a high risk of bleeding throughout a patient’s life [1, 2]. Little is known about the pathophysiological processes in an AVM and even less about any factors which could predict a risk of bleeding. The black blood MRI (bbMRI) appeared on the diagnostic horizon and offers a promising outlook in predicting rupture risk in intracranial aneurysms [3, 4]. As contrast enhancement in the aneurysm wall reflects inflammatory processes and inflammation in the AVM vessel wall has been shown histologically [5], we studied the possibility of bbMRI on high flow AVMs in order to evaluate differences in inflammatory processes which could signify instability. One study with 4 patients using ferumoxytol-enhanced MRI showed the feasibility of MRIs in visualizing inflammation in AVMs [6]. A study on cavernomatous malformations conducted by our group showed no significant contrast enhancement of the walls of brain cavernomas (low flow malformations, results submitted for publication). The main question was whether inflammatory reactions in the walls of high flow malformations can be visualized by bbMRI and...
whether the contrast enhancement can predict any status of instability of an AVM.

**Methods**

From January 2017 until July 2017 patients with AVMs treated in our department received a bbMRI sequence in addition to the regular MRI. We retrospectively analyzed the MRIs of 10 patients with AVMs treated in our department. In addition, \( N = 4 \) patients with arteriovenous fistulas received a bbMRI. The patients presented in our outpatient facilities or in case of AVM bleeding in the emergency room. The analysis of bbMRIs was performed by a neuroradiologists and the result of contrast enhancement in the AVM was rated as positive or negative.

**Table 1** Characteristics of the study population

| Gender | Age | S-M | Localization | Hemorrhage | Size | Treatment | Contrast enhancement in black blood MRI |
|--------|-----|-----|--------------|------------|------|-----------|----------------------------------------|
| Male   | 51 y | 1   | temporal     | non bleeding | 25 mm | Surgery   | Contrast at fistulas                    |
| Female | 19 y | 1   | temporal     | bleeding    | 15 mm | Surgery   | Contrast at nidus                       |
| Male   | 19 y | 2   | frontal      | bleeding    | 14 mm | Surgery   | Contrast at nidus                       |
| Male   | 53 y | 2   | frontal      | bleeding    | 15 mm | Surgery   | Contrast at nidus                       |
| Male   | 77 y | 2   | cerebellar   | bleeding    | 17 mm | Embolisation | Contrast at nidus                     |
| Male   | 46 y | 2   | frontal      | non bleeding | 9 mm  | Radiation | No contrast                             |
| Female | 49 y | 2   | parietal     | non bleeding | 36 mm | Observation | Contrast at nidus                      |
| Female | 53 y | 2   | temporal     | non bleeding | 33 mm | Surgery   | Contrast at nidus                       |
| Female | 61 y | 4   | Temporo-parietal | non bleeding | 46 mm | Observation | Contrast at fistulas                   |
| Male   | 57 y | 5   | fronto-parietal | non bleeding | 67 mm | Observation | Contrast at nidus                      |

**Fig. 1** Case with incidental AVM. 

a. Digital subtraction angiography showing the frontal AVM in sagittal (left) and b. coronal (right) views. c. BbMRI shows no contrast enhancement in the AVM.
negative. Three cases are illustrated. AVM size was defined as the longest diameter in mm.

Cranial MRI was performed on a 3T MR scanner (Magnetom Skyra, Siemens, Erlangen) with a 20 channel head coil. The protocol included a 3D T1 space sequence with fat saturation (SPAIR) and blood suppression (field of view 179x230, repetition time 693 ms, echo time 18 ms, matrix 256 x 256, spatial resolution 0.9 x 0.9 x 0.9 mm) before and after administration of gadolinium (0.2 ml/kg/BW, maximum 20 ml; ProHance, Bracco Imaging, Germany). Total scan time was 8 min.

Results

$N = 10$ patients with AVMs of which 4 were female received a bbMRI. The mean age of patients with bleeding AVMs ($N = 4$) was 42 y (19-77 y) and 52.8 y (46-61 y) for the non-bleeding cases. Five patients were operated on; 3 AVMs are still under observation, one was embolized and one irradiated. In 9 / 10 cases the AVM vessel walls showed contrast enhancement. Four patients presented with intracranial bleeding all of which showed strong contrast enhancement in their AVM niduses. Only one AVM with no haemorrhage and a Spetzler-Martin Grade 2 had no contrast enhancement. There was no difference in contrast enhancement between bleeding and non-bleeding AVMs. Additionally, the contrast enhancement was localized to the whole nidus, whereas in the 4 studied arteriovenous fistula patients the contrast enhancement was exclusively in the walls of the abnormal vein. All 4 patients with arteriovenous fistulas had contrast enhancement (2 with haemorrhage and 2 without). Further analysis of the patients with fistulous malformation was not possible due to the low sample size.

Table 1 summarizes some of the characteristics of the AVMs in the 10 studied patients.

Illustrative Cases

We show the typical bbMRI contrast enrichment in the AVMs in the following 3 cases.

The first case illustrates a 46 y.o. male patient who presented in our outpatient clinic with the diagnosis of an incidental AVM of 9 mm and a deep venous drainage. The bbMRI shows no contrast enhancement. Nevertheless, the patient was treated by radiation therapy (Fig. 1).

The second case is that of a 53 y.o. female patient who presented with an epileptic seizure. The AVM (Fig. 2) was known for over 10 years but after the seizure and an increase in size we decided to remove the AVM. Before surgery the bbMRI was performed and showed an intranidal contrast enhancement of the vascular walls (Fig.2).

The third case is of 61 y.o. female with an epileptic seizure. The diagnostic MRI revealed a 46 mm temporo-parietal AVM. The bbMRI shows contrast enhancement of the nidus (Fig. 3). Under antiepileptic therapy she did not have any new seizures and because she rejected surgery we decided to observe the patient.

Discussion

The present study evaluates feasibility of bbMRI for assessment of AVMs. It has been shown that inflammatory processes play a crucial role in AVM growth with increased expression of inflammatory cytokines and proteases in these lesions [7, 8]. Recruitment of leukocytes and leukocyte-derived metalloproteinases lead to structural degradation of the AVM walls which could lead to rupture [9]. On the other hand, macrophages and other inflammatory cells are detected in the vascular walls of AVMs which did not rupture [7, 8, 10]. Therefore, it cannot be concluded that the inflammation is a sign of AVM instability and a risk factor for rupture unlike in intracranial aneurysms [3, 4]. After demonstrating that bbMRI contrast enhancement is present in AVMs as well as in arteriovenous fistulas we looked for differences between ruptured and non-ruptured AVMs as well as size and inflammation. Although there is a strong uptake of contrast enhancement in the AVM nidus and in the abnormal vein of arteriovenous fistulas in the patients, indicating a high probability of ongoing inflammation there was no difference between ruptured and...
unruptured malformations in size. It can be concluded that there are dynamic inflammatory processes in AVMs and arteriovenous fistula walls but it seems that it is not more prevalent in AVMs prone to rupture. The observations of inflammation in AVM walls which could indicate a rupture risk have to be seen critically because unlike aneurysms, AVMs appear to be in a permanent stage of inflammation as seen in our study in which 6 /10 AVMs with no bleeding displayed strong contrast enhancement in bbMRI. The same phenomenon can be observed in the four cases of arteriovenous fistulas which were all contrast enhancing: there was no difference between the haemorrhaged (2 out of 4) and the non-haemorrhaged cases but sample sizes are of course low.

Never the less the number of patients studied does not allow drawing of conclusions other than that bbMRI is feasible in indicating inflammation in AVMs and that AVMs are highly active in terms of inflammatory processes. Based on this first observation with bbMRI further prospective and controlled studies looking for differences between stable AVMs and those prone to rupture are needed. Objective criteria of inflammatory activity could be of use in determining which AVMs should be treated and which are to be observed.

**Conclusions**

The study is the first one using black blood MRI in AVMs. What we could show is an indication of a high inflammatory activity in the AVM wall speaking for a possible instability. Never the less and because of the small case number, it has to be evaluated in a prospective study if the inflammatory activity seen in the black blood MRI is associated with a higher bleeding rate. Histological specimens of AVMs together with black blood MRIs should be evaluated in further studies.

**Abbreviations**

AVM: Arteriovenous Malformations; bbMRI: Black Blood Magnetic Resonance Imaging; ARUBA: A Randomised Trial of Unruptured Brain Arteriovenous Malformations.

---

**Fig. 3** Non-hemorrhaged temporoparietal AVM. a MR-Angiography (left) and b reconstruction (right) of the AVM. c In the bbMRI (w/o contrast, left and d with contrast, right) there is a strong contrast enhancement of the AVM nidus.
Acknowledgement
We hereby take opportunity to thank the Department of Neurosurgery and the Institute of neuroradiology of the Heinrich Heine University, Düsseldorf, Germany for their constant supports throughout the period of this study.

Funding
This study did not receive any grant funding.

Availability of data and supporting materials
Data sharing not applicable to this article

Authors’ contributions
HJS and BT participated in the design of the study. AKP and MDA participated in the patient selection, design of the study, surgical follow-up and co-ordination of manuscript drafting. YA, MS, LL - Patient follow-up, drafting and correction of the manuscript. JFC, MAK, RM – Valuable input in decision making, treatment option and interpretation of the MRI and BB-MRI. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For retrospective studies like the present one there is no ethical approval needed according to the Physicians Chamber (Ärtzekammer Nordrhein). All patients of the study were informed orally about possible presentation of their data, however no identification of the patient is possible in the presented data. There are no individual images of the patients contained in this manuscript.

Competing interests
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Maxine Dibué-Adjei is an employee of LivaNova PLC, manufacturer of vagus nerve stimulators.

Consent for Publication
Not applicable. This is not a case report. As long as the patient can not be identified in the images presented no informed consent is needed. However, the patient was orally informed and consented to publish his case.

Author details
1Department of Neurosurgery, Heinrich Heine University, Düsseldorf, Germany. 2LivaNova Deutschland GmbH (a LivaNova PLC-owned subsidiary), Lindberghstr 25, D-80939 Munich, Germany. 3Diagnostic and Interventional Neuroradiology, Heinrich Heine University, Düsseldorf, Germany. 4Department of Neurosurgery, Niederrhein Hospital, Duisburg, Germany.

Received: 5 December 2017 Accepted: 9 May 2018
Published online: 25 May 2018

References
1. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicenter, non-blinded, randomized trial. Lancet. 2014;383:614–21.
2. Petridis AK, Fischer I, Cornelius JF, Kamp MA, Ringel F, Tortora A, et al. Demographic distribution of hospital admissions for brain arteriovenous malformations in Germany—estimation of the natural course with the big-data approach. Acta Neurochir (Wien). 2016;158(4):791–6.
3. Hu P, Yang Q, Wang D, Guan S, Zhang H. Wall enhancement on high-resolution magnetic resonance imaging may predict an unsteady state of an intracranial saccular aneurysm. Neuroradiol. 2016;58:769–83.
4. Park JK, Lee CS, Sim KB, Huh JS, Park JC. Imaging of the walls of saccular cerebral aneurysms with double inversion recovery black-blood sequence. J Magn Res Imag. 2009;30:1179–83.
5. Zhang R, Han Z, Degos V, Shen F, Choi EJ, Sun Z, et al. Persistent infiltration and pro-inflammatory differentiation of monocytes cause unresolved inflammation in brain arteriovenous malformation. Angiogenesis. 2016;19(4):451–61.
6. Zaraty M, Chalouhi N, Starke RM, Jabbour P, Hasan D. Molecular Imaging in Neurovascular Diseases: The Use of Ferumoxytol to Assess Cerebral Aneurysms and Arteriovenous Malformations. Top Magn Reson Imaging. 2016;25(2):57–61.
7. Chen Y, Fan Y, Poon KY, Achrol AS, Lawton MT, Zhu Y, et al. MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Front. Biosci. 2006;11:3121–8.
8. Chen Y, Pavlikowska L, Yao JS, Shen F, Zhai W, Achrol AS, et al. Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol. 2006;59:72–80.
9. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18:1163–72.
10. Chen Y, Zhu W, Bollen AW, Lawton MT, Barbaro NM, Dowd CF, et al. Evidence of inflammatory cell involvement in brain arteriovenous malformations. Neurosurgery. 2008;62(6):1340–9.

Petridis et al. Chinese Neurosurgical Journal (2018) 4:13

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions